Literature DB >> 9829151

Factors in improved survival from paediatric cancer.

J W Taub1.   

Abstract

In 1998, over two-thirds of children diagnosed with cancer will be cured of their disease. This has been accomplished by improvements in understanding the biology of the various forms of cancer and stratifying protocol-based therapies (surgery, radiotherapy and chemotherapy) based on predicted treatment outcome and risk of treatment failure. The excellent prognosis of subgroups of malignancies, including acute lymphoblastic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma and Wilms' tumour, has led to the modification of therapies to decrease or minimise long term adverse effects which may have a significant impact on the quality of life of survivors. The lessons learned from the treatment of paediatric cancer may lead to improvements in the treatment of adult cancers.

Entities:  

Mesh:

Year:  1998        PMID: 9829151     DOI: 10.2165/00003495-199856050-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  80 in total

1.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

Review 2.  Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).

Authors:  M Smith; P T Ho
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Genetic disease in offspring of long-term survivors of childhood and adolescent cancer.

Authors:  J Byrne; S A Rasmussen; S C Steinhorn; R R Connelly; M H Myers; C F Lynch; J Flannery; D F Austin; F F Holmes; G E Holmes; L C Strong; J J Mulvihill
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

4.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

5.  High risk of breast carcinoma after irradiation of young women with Hodgkin's disease.

Authors:  A C Aisenberg; D M Finkelstein; K P Doppke; F C Koerner; J F Boivin; C G Willett
Journal:  Cancer       Date:  1997-03-15       Impact factor: 6.860

6.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

Authors:  E Masson; M V Relling; T W Synold; Q Liu; J D Schuetz; J T Sandlund; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

7.  Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.

Authors:  A Reiter; M Schrappe; R Parwaresch; G Henze; S Müller-Weihrich; S Sauter; K W Sykora; W D Ludwig; H Gadner; H Riehm
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

8.  Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative.

Authors:  C H Pui; S C Raimondi; M L Hancock; G K Rivera; R C Ribeiro; H H Mahmoud; J T Sandlund; W M Crist; F G Behm
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

9.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.

Authors:  S A Shurtleff; A Buijs; F G Behm; J E Rubnitz; S C Raimondi; M L Hancock; G C Chan; C H Pui; G Grosveld; J R Downing
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

10.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.

Authors:  T W Synold; M V Relling; J M Boyett; G K Rivera; J T Sandlund; H Mahmoud; W M Crist; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.